drugset
drugset / Trial / NCT00509821

Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma

NCT00509821 ↗

Phase 2 Completed 60 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the protocol was to induce a novel radiochemotherapy with enzastaurin as first-line treatment regimen in glioblastoma: Participants with active, unmethylated MGMT promoter were treated with enzastaurin before, concomitant, and after radiotherapy to determine safety and PFS at 6 months (PFS-6) in phase II.

Timeline

Start
2007-10
Primary completion
2010-02
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 250 mg Oral
Subject enzastaurin Small molecule 500 mg Oral

Indications

glioblastoma